The U.S. biopharma sector continues to innovate at pace, fuelled by advances in biologics, precision medicine, and AI‑enabled drug discovery.
The broader biopharmaceutical industry, including biologics and advanced therapies, is now on track to expand from an estimated ~USD 507 billion in 2025 to over USD 1 trillion by the early 2030s.
Yet turning scientific breakthroughs into global patient access remains a persistent challenge. While new medicines regularly gain FDA approval, many struggle to gain traction — or even access — outside the U.S.
The result? Patients in major healthcare systems wait years for new treatments, and biopharma companies miss revenue opportunities they forecasted based on domestic performance.
Why is this happening and how can U.S. innovators do better? The answer lies in strategy, not just science…
Why exporting a U.S. strategy doesn’t work
A common rhythm in U.S. biopharma is to prioritise FDA approval, then adapt the U.S. commercial blueprint for the rest of the world.
This often assumes that regulatory clearance and strong domestic uptake will naturally translate to success overseas.
But healthcare systems differ radically – in evidence standards, payer expectations, competitive landscapes, and cultural norms.
Too often, when a product struggles internationally, the reflex is to conclude the drug itself failed. In reality, it’s usually the commercialisation strategy that wasn’t designed for global conditions.
Here’s how companies should rethink global launch planning from the outset.
1) Start with evidence aligned to global decision makers
The clinical evidence package you design affects every downstream commercialisation discussion.
In the U.S., surrogate endpoints — like tumour shrinkage or biomarker changes — often suffice for approval and commercial uptake.
But outside the U.S., many HTA bodies prioritise long‑term outcomes like overall survival and quality‑adjusted life years.
For example:
- HTA bodies including NICE in the U.K. scrutinise surrogate outcomes without robust validation.
- Japan’s regulator (PMDA) often requests evidence from local patients rather than global populations alone.
Without early alignment of trial design to these global requirements, companies risk delays of 2–3 years (or more) in reimbursement and access.
To avoid this, evidence planning must begin in Phase II and integrate requirements for local comparators, health economic models, and real‑world evidence.
2) Think with a payer mindset — not Just a U.S. pricing mindset
Price negotiations in the U.S. typically centre on speed to market and physician adoption, with payers negotiating list prices with insurers.
Elsewhere, affordability and cost‑effectiveness determine whether a therapy ever becomes reimbursed.
Key regional expectations include:
- Europe: HTA bodies expect rigorous pharmacoeconomic models and strong comparator data.
- Australia: PBAC submissions often fail first time due to insufficient health economic evidence.
- South Korea: Negotiations frequently involve risk‑sharing arrangements.
Failing to match local payer expectations isn’t just inconvenient, it can fundamentally block patient access.
3) Understand local competitive and care delivery contexts
Even products with strong clinical profiles can struggle if they enter crowded markets without a compelling differentiator.
For instance, a U.S. GLP‑1 diabetes therapy that dominated domestically found limited room in Europe because entrenched competitors already held broad indications and strong physician familiarity. Competing against these incumbents without a tailored strategy slowed uptake and limited impact.
Similarly, healthcare delivery preferences vary:
- Hospital‑administered therapies may be favourable in some regions because they align with provider incentives.
- Other markets reward self‑administration to reduce healthcare system burden.
Mapping the local standard of care and where your product fits within it should inform positioning, pricing, and launch sequencing long before commercial activation.
4) Respect cultural and system nuances
Cultural expectations and care delivery norms have real commercial consequences.
For example:
- Infusion centres may be seen as routine community touchpoints in Italy, whereas convenience and minimal disruption drive preference in the U.K.
- Physician prescribing behaviour (such as antibiotic practices) differs markedly between regions, reflecting local public health priorities.
Bringing these insights into strategy development ensures messaging and access pathways resonate with physicians, payers and patients across geographies.
5) Get real about pricing and global reference dynamics
U.S. pricing pressures are reshaping global dynamics. Medicare price negotiations and new reference mechanisms (e.g., linking U.S. prices to peer economies) mandate that global pricing strategies are no longer siloed. Companies can no longer rely on high U.S. list prices to subsidise access globally.
At the same time, markets such as China and Brazil enforce strict price controls and reference pricing, requiring deeper planning around affordability and inclusion in national reimbursement lists.
The net result is clear: global pricing strategy matters early and everywhere — not just after FDA approval.
6) Plan early and collaborate across functions and regions
Delaying global strategy until Phase III or after FDA approval locks in evidence and positioning that may be sub‑optimal elsewhere. That’s why the most successful companies now:
- Involve global teams during evidence planning
- Use collaborative platforms to align on payer evidence, comparators and pricing assumptions
- Build strategies iteratively with early feedback from local affiliates
This cross‑functional collaboration ensures strategy isn’t imposed from a distant HQ, but shaped with real‑world insights from the regions where patients will be treated.
7) Map patient journeys and sequence intelligently
With global evidence and commercial strategy aligned, biopharma teams can map patient journeys to identify shared barriers and local differences. This dual lens strengthens global messaging while enabling tailored local execution.
Smart sequencing (choosing which markets to prioritise based on unmet need, competitive intensity and payer willingness) prevents overpromising and aligns commercial efforts with realistic access pathways.
From breakthrough science to global access
Global commercialisation isn’t about replicating a U.S. launch playbook overseas. It’s about building a global strategy grounded in evidence, local insights and cross‑functional collaboration.
For U.S. biopharma companies, the opportunity is clear: by planning earlier, aligning pricing and evidence to real payer expectations, and empowering teams with local knowledge, it’s possible to turn innovation into meaningful patient access worldwide — not just commercial success at home. Discover how Nmblr can support your teams to unlock worldwide access.